EurekAlert!

Most patients with mitochondrial disease can be diagnosed via genomic sequencing

More than half of people with mitochondrial disease can be diagnosed via genomic sequencing, a finding that will revolutionise care for families, according to a new study. And the Melbourne ...
MedPage Today on MSN

Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug

The FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare ...
MyHorryNews

U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

KYGEVVI™ (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 ...

Tisento Therapeutics Announces Publication of MELAS Interview Study, Incorporating Patients’ Perspectives to Elucidate Symptoms and Impacts of Rare Mitochondrial Disease

Tisento Therapeutics today announced that the findings from the company’s interview study in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes) were published on ...
BioSpace

UCB Wins First FDA Approval for Ultra-Rare Mitochondrial Disease

Kygevvi is indicated for patients with thymidine kinase 2 deficiency whose symptoms arise by 12 years of age. The disease ...

FDA approves first drug for Thymidine Kinase 2 Deficiency: All we know about this very rare mitochondrial disease

A groundbreaking FDA approval offers the first-ever treatment for ultra-rare Thymidine Kinase 2 Deficiency (TK2d). KYGEVVI, a ...
Fierce Pharma

On a roll, UCB picks up another rare disease FDA approval

UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian ...
Andover Advertiser

The Abel Foundation supporting mitochondrial disease

The Abel Foundation, based in Andover is a charity has spent years providing vital support to families affected by.

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and ...

FDA Approves KYGEVVI® (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 deficiency (TK2d), a Rare and Devastating Mitochondrial Disease ...